Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
polyserp-m
- Development stage
- Unknown
- Lead developer
- Polyserp Therapeutics
- Modality
- Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Polyserp-M (also known as POLYSERP MENA) is a polyvalent antivenom developed by Polyserp Therapeutics for the treatment of snake envenomation. It is composed of equine-derived polyclonal F(ab')2 immunoglobulin fragments designed to neutralize the venoms of 27 medically significant snake species found across the Middle East, North Africa, and Central Asia. The product provides broad-spectrum coverage against both elapid and viperid species prevalent in these regions and is approved for clinical use.
- Brand names
- POLYSERP MENA
- Other names
- POLYSERP-MPOLYSERP MENA
Beyond the preview
Go deeper on polyserp-m.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on polyserp-m.